ImageneBio Inc. (IMA)
NASDAQ: IMAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IMA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $48.83M
- EPS (TTM)
- -$2.11
- Dividend yield
- None
- 52-week range
- 3.00 – 7.60
- Day range
- 3.79 – 4.04
- Volume / Avg
- 44.34K / 15.86K
- Beta
- —
- Shares outstanding
- 12.46M
52-week range
IMA stock today
ImageneBio (IMA) closed at $3.92 on Nov 20, essentially unchanged from the prior close, versus the S&P 500's 3.70% decline. Volume was 2.8x the average at 44.34K shares, a sign of unusually heavy trading. Shares are 48.4% below their 52-week high of $7.60, set on Jan 30, 2026 and 30.7% above the 52-week low of $3.00, near the bottom of the past year's range.
IMA is down 43.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 44.9%. ImageneBio has posted a net loss over the last twelve months (EPS of -$2.11), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About ImageneBio
Company profileImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Kristin Yarema Ph.D.
- Headquarters
- San Diego, CA
- Employees
- 18
- IPO year
- 2021
- Website
- inmagenebio.com
Financial highlights
Full financialsIn fiscal 2025, ImageneBio generated $800,000 in revenue, down 77.1% from fiscal 2024, its first annual decline since 2024. ImageneBio reported a net loss of $45.3 million, compared with a loss of $36.6 million a year earlier. Operating margin was -6056.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $800.00K | $3.50M | $9.16M | $15.62M | $30.98M |
| Growth | -77.14% | -61.79% | -41.35% | -49.59% | +237.01% |
| Net income | $-45.35M | $-36.57M | $-68.17M | $-68.77M | $-34.12M |
| EPS (diluted) | $-9.64 | $-22.10 | $-1.63 | $-1.90 | $-1.22 |
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$18.00+359.18%
- Strong buy 0
- Buy 3
- Hold 0
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.91 vs $-0.83
- Surprise
- -9.64%
ImageneBio peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AVXLAnavex Life Sciences Corp. | 0.5915 | -11.39% | $54.83M | vs IMA |
| GRMLGreenland Mines Ltd. | 2.99 | +2.75% | $44.31M | vs IMA |
| CGTXCognition Therapeutics Inc. | 0.5822 | -3.06% | $55.37M | vs IMA |
| ELOXEloxx Pharmaceuticals Inc. | 10.69 | -1.75% | $43.69M | vs IMA |
| OKYOOKYO Pharma Limited | 1.07 | -7.76% | $56.15M | vs IMA |
| CHRSCoherus Oncology Inc. | 0.3698 | -4.47% | $57.15M | vs IMA |
| INKTMiNK Therapeutics Inc. | 8.02 | -6.85% | $41.17M | vs IMA |
| ELUTElutia Inc. Class A | 0.9001 | +11.12% | $39.96M | vs IMA |
Indexes, lists and sector
ImageneBio stock FAQ
What is ImageneBio's stock price today?
IMA last traded at $3.92 as of Nov 20, 4:00 PM EST, up 0.00% on the day. Prices are delayed at least 15 minutes.
Does ImageneBio pay a dividend?
No. ImageneBio does not currently pay a regular cash dividend.
Who is ImageneBio's CEO?
Dr. Kristin Yarema Ph.D. is the chief executive officer of ImageneBio Inc., which has about 18 employees.
Has IMA ever split its stock?
Yes. The most recent IMA stock split was a 1-for-12 split on Jul 28, 2025.
What is the IMA 52-week high?
The 52-week high for IMA is $7.60 and the 52-week low is $3.00. The stock is currently 48.4% below its high.